Merli, Francesco

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 125

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 114

Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients

Potenza, L., Vallerini, D., Barozzi, P., Riva, G., Forghieri, F., Beauvais, A., Beau, R., Candoni, A., Maertens, J., Rossi, G., et al. (2013) · PLoS ONE

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 81